Free tool
FAERS Monitor: Stalevo 75
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021485 or its brand name (Stalevo 75, Carbidopa, Entacapone, Levodopa). Reports on generic versions are filed under their own applications.
Reports
481
Serious
355
74% of reports
Hospitalization
194
Death reported
88
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- fall69
- death54
- hallucination52
- drug ineffective43
- parkinson^s disease41
- dyskinesia27
- urinary tract infection27
- product dose omission issue25
- confusional state24
- device issue21
- fatigue18
- somnolence18
- asthenia17
- gait disturbance17
- insomnia17
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2011 | 3 |
| 2012 | 1 |
| 2013 | 3 |
| 2014 | 4 |
| 2015 | 3 |
| 2016 | 9 |
| 2017 | 34 |
| 2018 | 42 |
| 2019 | 38 |
| 2020 | 61 |
| 2021 | 57 |
| 2022 | 64 |
| 2023 | 60 |
| 2024 | 46 |
| 2025 | 56 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,678 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| hallucinationSignal | 52 | 30.2 | 23.4 | 1,443 |
| dyskinesiaSignal | 27 | 29.1 | 20.1 | 705 |
| device issueSignal | 21 | 10.2 | 6.7 | 167 |
| fallSignal | 69 | 9.1 | 7.3 | 495 |
| urinary tract infectionSignal | 27 | 6.9 | 4.8 | 132 |
| confusional stateSignal | 24 | 6.5 | 4.4 | 107 |
| somnolenceSignal | 18 | 3.9 | 2.5 | 36 |
| gait disturbanceSignal | 17 | 3.9 | 2.4 | 34 |
| product dose omission issueSignal | 25 | 3.7 | 2.5 | 48 |
| insomniaSignal | 17 | 2.8 | 1.7 | 18 |
| deathSignal | 54 | 2.7 | 2.1 | 60 |
| asthenia | 17 | 2.0 | 1.2 | 7 |
| drug ineffective | 43 | 1.4 | 1.1 | 5 |
| fatigue | 18 | 1.0 | 0.6 | 0 |
| parkinson^s disease | 41 | 0.0 | 0.0 | 1,751,095 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.